{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:04:27Z","timestamp":1790773467613,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,7]]},"abstract":"<jats:p>Recent studies have identified a novel programmed cell death based on copper, named cuproptosis. However, as an anti-cuproptosis gene, the functional roles, definite mechanisms and prognostic value of CDKN2A in pan-cancer are largely unclear. The GEPIA2, cancer genome atlas (TCGA), the tumor immune estimation resource 2.0 and CPTAC databases were performed to validate the differential expression of CDKN2A in 33 tumors. The clinical features and survival prognosis analysis were conducted by GEPIA2 and UALCAN web tool. Genetic alteration analysis of CDKN2A in pan-cancer was also evaluated. Furthermore, the functional roles of CDKN2A were explored via DNA methylation analysis, tumor microenvironment, infiltration of immune cells, enrichment analysis and gene co-expression associated with cuproptosis and immune regulation. The CDKN2A expression, both at the transcriptional and translational level, was obviously upregulated in most cancer patients, which might lead to poor survival in certain cancer types. CDKN2A expression was significantly associated with tumor pathological stages in some cancer types. In adrenocortical carcinoma (ACC) and kidney renal clear cell carcinoma (KIRC), DNA methylation of CDKN2A was explored to induce poor clinical outcomes. Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis indicated that CDKN2A expression was closely related to several cancer-associated signaling pathways, such as the p53 signaling pathway, Cellular senescence, DNA replication and Cell cycle signaling pathways. Gene set enrichment analysis (GSEA) analysis suggested that aberrantly expressed CDKN2A took part in the cell cycle regulation, immune regulation and mitochondrial signaling pathways in certain cancer patients. In addition, aberrant CDKN2A expression was closely correlated to immune infiltration and the levels of immune-regulatory genes. The study deeply defined the concrete roles of cuproptosis-related gene CDKN2A in tumorigenesis. The results provided new insights and pieces of evidence for treatment.<\/jats:p>","DOI":"10.1097\/md.0000000000033468","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T13:17:04Z","timestamp":1680873424000},"page":"e33468","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2540-5795","authenticated-orcid":false,"given":"Di","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, China"},{"name":"Tianjin Institute of Coloproctology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, China"},{"name":"Tianjin Institute of Coloproctology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, China"},{"name":"Tianjin Institute of Coloproctology, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0620-8238","authenticated-orcid":false,"given":"Xipeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, China"},{"name":"Tianjin Institute of Coloproctology, Tianjin, China"},{"name":"The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide.","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrm3737","article-title":"Regulated necrosis: the expanding network of non-apoptotic cell death pathways.","volume":"15","author":"Vanden Berghe","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.18632\/aging.204302","article-title":"Pyroptosis patterns of colon cancer could aid to estimate prognosis, microenvironment and immunotherapy: evidence from multi-omics analysis.","volume":"14","author":"Zhou","year":"2022","journal-title":"Aging (Milano)"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1038\/s41598-022-20217-4","article-title":"Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients.","volume":"12","author":"Hua","year":"2022","journal-title":"Sci Rep"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"eabm9427","DOI":"10.1126\/sciadv.abm9427","article-title":"Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction.","volume":"8","author":"Fujihara","year":"2022","journal-title":"Sci Adv"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbcan.2019.01.006","article-title":"The role of necroptosis in cancer: a double-edged sword?","volume":"1871","author":"Qin","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins.","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/tox.21916","article-title":"Copper-induced immunotoxicity involves cell cycle arrest and cell death in the liver.","volume":"30","author":"Keswani","year":"2015","journal-title":"Environ Toxicol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"16867","DOI":"10.18632\/aging.103585","article-title":"Oxidative stress, apoptosis and inflammatory responses involved in copper-induced pulmonary toxicity in mice.","volume":"12","author":"Jian","year":"2020","journal-title":"Aging (Milano)"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nchembio.72","article-title":"Mechanisms for copper acquisition, distribution and regulation.","volume":"4","author":"Kim","year":"2008","journal-title":"Nat Chem Biol"},{"key":"R12-20250504","first-page":"4074","article-title":"Pan-cancer profiles of the cuproptosis gene set.","volume":"12","author":"Liu","year":"2022","journal-title":"Am J Cancer Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2022.07.016","article-title":"Therapeutic strategies for targeting CDKN2A loss in melanoma.","volume":"143","author":"Kreuger","year":"2023","journal-title":"J Invest Dermatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/bjc.2013.251","article-title":"The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis.","volume":"108","author":"Xing","year":"2013","journal-title":"Br J Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/SLA.0b013e3182827a65","article-title":"Immunohistochemically detected expression of 3 major genes (CDKN2A\/p16, TP53, and SMAD4\/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.","volume":"258","author":"Oshima","year":"2013","journal-title":"Ann Surg"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"14383","DOI":"10.1038\/s41598-018-32569-x","article-title":"CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.","volume":"8","author":"Worst","year":"2018","journal-title":"Sci Rep"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apm.12744","article-title":"Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma.","volume":"125","author":"Ryu","year":"2017","journal-title":"APMIS"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2017.01.028","article-title":"Loss of p16(INK4A) expression and homozygous CDKN2A deletion are associated with worse outcome and younger age in thymic carcinomas.","volume":"12","author":"Aesif","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41467-021-27889-y","article-title":"Age influences on the molecular presentation of tumours.","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12876-022-02257-2","article-title":"Identification and validation of EMT-immune-related prognostic biomarkers CDKN2A, CMTM8 and ILK in colon cancer.","volume":"22","author":"Kang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"BSR20211103","DOI":"10.1042\/BSR20211103","article-title":"CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.","volume":"41","author":"Luo","year":"2021","journal-title":"Biosci Rep"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1074123","DOI":"10.3389\/fphar.2022.1074123","article-title":"Prognostic and immune correlation evaluation of a novel cuproptosis-related genes signature in hepatocellular carcinoma.","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/genes13050851","article-title":"A novel cuproptosis-related prognostic gene signature and validation of differential expression in clear cell renal cell carcinoma.","volume":"13","author":"Bian","year":"2022","journal-title":"Genes"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"912037","DOI":"10.3389\/fgene.2022.912037","article-title":"Identification and validation of cuproptosis-related prognostic signature and associated regulatory axis in uterine corpus endometrial carcinoma.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Genet"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells.","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses.","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/epi-2017-0118","article-title":"MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data.","volume":"10","author":"Modhukur","year":"2018","journal-title":"Epigenomics"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"758926","DOI":"10.3389\/fgene.2021.758926","article-title":"Recognition of DNA methylation molecular features for diagnosis and prognosis in gastric cancer.","volume":"12","author":"Liu","year":"2021","journal-title":"Front Genet"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","article-title":"CDKN2A alterations and response to immunotherapy in solid tumors.","volume":"27","author":"Adib","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13053-021-00178-x","article-title":"CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.","volume":"19","author":"Chan","year":"2021","journal-title":"Hered Cancer Clin Pract"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.12998\/wjcc.v10.i22.7686","article-title":"Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer.","volume":"10","author":"Wang","year":"2022","journal-title":"World J Clin Cases"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"970950","DOI":"10.3389\/fimmu.2022.970950","article-title":"CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Immunol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.3748\/wjg.v27.i34.5737","article-title":"MTNR1B polymorphisms with CDKN2A and MGMT methylation status are associated with poor prognosis of colorectal cancer in Taiwan.","volume":"27","author":"Lee","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"749779","DOI":"10.3389\/fchem.2021.749779","article-title":"The GW miracle in many-body perturbation theory for the ionization potential of molecules.","volume":"9","author":"Bruneval","year":"2021","journal-title":"Front Chem"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-21-4316","article-title":"Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer.","volume":"28","author":"Deneka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/path.5970","article-title":"Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions.","volume":"258","author":"Liu","year":"2022","journal-title":"J Pathol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.26069","article-title":"CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.","volume":"96","author":"Wang","year":"2021","journal-title":"Am J Hematol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"50071","DOI":"10.18632\/oncotarget.18412","article-title":"CDKN2A methylation in esophageal cancer: a meta-analysis.","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"e0182","DOI":"10.1097\/MD.0000000000010182","article-title":"Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).","volume":"97","author":"Cao","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1039\/C9FO01168D","article-title":"Prediction of new targets and mechanisms for quercetin in the treatment of pancreatic cancer, colon cancer, and rectal cancer.","volume":"10","author":"Pang","year":"2019","journal-title":"Food Funct"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression.","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies.","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front Immunol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment.","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy.","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer.","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"BSR20221082","DOI":"10.1042\/BSR20221082","article-title":"INK4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma.","volume":"42","author":"Liu","year":"2022","journal-title":"Biosci Rep"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"778294","DOI":"10.3389\/fphar.2021.778294","article-title":"An inflammatory response related gene signature associated with survival outcome and gemcitabine response in patients with pancreatic ductal adenocarcinoma.","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Pharmacol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.coi.2020.03.004","article-title":"Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy.","volume":"64","author":"Barrett","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"e57243","DOI":"10.7554\/eLife.57243","article-title":"Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy.","volume":"9","author":"Barrett","year":"2020","journal-title":"eLife"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jcmm.14745","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in cancer.","volume":"24","author":"An","year":"2020","journal-title":"J Cell Mol Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:27:00Z","timestamp":1746325620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":54,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033468","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}